SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial

SELLAS Life Sciences Group, Inc.

2024-Q1 EPS reported -$0.21

Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.
Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.
IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.
SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.
Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.

Period: the first quarter ended March 31, 2024
Net income: $9.6 million
EPS: $0.21
Result: reported results

Exact text from the filing

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

View on SEC.gov

Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.